JP2016517517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517517A5 JP2016517517A5 JP2016501142A JP2016501142A JP2016517517A5 JP 2016517517 A5 JP2016517517 A5 JP 2016517517A5 JP 2016501142 A JP2016501142 A JP 2016501142A JP 2016501142 A JP2016501142 A JP 2016501142A JP 2016517517 A5 JP2016517517 A5 JP 2016517517A5
- Authority
- JP
- Japan
- Prior art keywords
- analyte
- sample
- concentration
- output signal
- normalized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012491 analyte Substances 0.000 claims description 383
- 239000000523 sample Substances 0.000 claims description 244
- 238000004458 analytical method Methods 0.000 claims description 115
- 238000000034 method Methods 0.000 claims description 106
- 238000012360 testing method Methods 0.000 claims description 71
- 239000013074 reference sample Substances 0.000 claims description 56
- 238000010606 normalization Methods 0.000 claims description 44
- 230000004044 response Effects 0.000 claims description 31
- 238000012935 Averaging Methods 0.000 claims description 23
- 238000003860 storage Methods 0.000 claims description 19
- 238000004891 communication Methods 0.000 claims description 10
- 230000009897 systematic effect Effects 0.000 claims description 6
- 238000005259 measurement Methods 0.000 description 96
- 210000004369 blood Anatomy 0.000 description 40
- 239000008280 blood Substances 0.000 description 40
- 230000006870 function Effects 0.000 description 39
- 230000003287 optical effect Effects 0.000 description 34
- 108091006146 Channels Proteins 0.000 description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 33
- 239000008103 glucose Substances 0.000 description 33
- 230000007717 exclusion Effects 0.000 description 29
- 238000005534 hematocrit Methods 0.000 description 17
- 239000013060 biological fluid Substances 0.000 description 16
- 239000004020 conductor Substances 0.000 description 15
- 238000012417 linear regression Methods 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 102000001554 Hemoglobins Human genes 0.000 description 12
- 108010054147 Hemoglobins Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000006479 redox reaction Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- 238000012545 processing Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000004082 amperometric method Methods 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000007613 environmental effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000000704 physical effect Effects 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000004832 voltammetry Methods 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 238000003869 coulometry Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000840 electrochemical analysis Methods 0.000 description 2
- 238000002848 electrochemical method Methods 0.000 description 2
- 238000012886 linear function Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 101001125200 Drosophila melanogaster Glutamate [NMDA] receptor subunit 1 Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 102220555409 Wnt inhibitory factor 1_H32G_mutation Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000004313 potentiometry Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361781950P | 2013-03-14 | 2013-03-14 | |
| US61/781,950 | 2013-03-14 | ||
| PCT/US2014/023069 WO2014159333A1 (en) | 2013-03-14 | 2014-03-11 | System error compensation of analyte concentration determinations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018006329A Division JP6494813B2 (ja) | 2013-03-14 | 2018-01-18 | 分析物濃度決定のシステム誤差補償 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016517517A JP2016517517A (ja) | 2016-06-16 |
| JP2016517517A5 true JP2016517517A5 (enExample) | 2017-04-06 |
| JP6280203B2 JP6280203B2 (ja) | 2018-02-14 |
Family
ID=50588807
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501142A Active JP6280203B2 (ja) | 2013-03-14 | 2014-03-11 | 分析物濃度決定のシステム誤差補償 |
| JP2018006329A Active JP6494813B2 (ja) | 2013-03-14 | 2018-01-18 | 分析物濃度決定のシステム誤差補償 |
| JP2019039413A Active JP7066649B2 (ja) | 2013-03-14 | 2019-03-05 | 分析物濃度決定のシステム誤差補償 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018006329A Active JP6494813B2 (ja) | 2013-03-14 | 2018-01-18 | 分析物濃度決定のシステム誤差補償 |
| JP2019039413A Active JP7066649B2 (ja) | 2013-03-14 | 2019-03-05 | 分析物濃度決定のシステム誤差補償 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10330629B2 (enExample) |
| EP (1) | EP2972397B1 (enExample) |
| JP (3) | JP6280203B2 (enExample) |
| CN (3) | CN110426436B (enExample) |
| CA (1) | CA2902541A1 (enExample) |
| IL (1) | IL240816B (enExample) |
| TW (2) | TWI624666B (enExample) |
| WO (1) | WO2014159333A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101929057B1 (ko) * | 2010-03-22 | 2018-12-13 | 바이엘 헬쓰케어 엘엘씨 | 바이오센서를 위한 잔여 보상 |
| PL3380839T3 (pl) * | 2015-11-23 | 2020-03-31 | F. Hoffmann-La Roche Ag | Sposób i urządzenie do określania stężenia analitu w płynie ustrojowym |
| CN107643335B (zh) * | 2016-07-20 | 2020-06-26 | 复凌科技（上海）有限公司 | 一种检测水环境的方法 |
| CN106596962B (zh) * | 2016-11-01 | 2018-07-03 | 武汉璟泓万方堂医药科技股份有限公司 | 一种基于血糖试纸测试值衰减的code定值修正方法 |
| US12100488B2 (en) | 2016-11-29 | 2024-09-24 | National Institute For Materials Science | Method and device for estimating value to be estimated associated with specimen |
| US10638979B2 (en) * | 2017-07-10 | 2020-05-05 | Glysens Incorporated | Analyte sensor data evaluation and error reduction apparatus and methods |
| WO2020234728A1 (en) * | 2019-05-21 | 2020-11-26 | Ascensia Diabetes Care Holdings Ag | Compensation system and method for thermistor sensing in an analyte biosensor |
| CN118758924B (zh) * | 2024-09-06 | 2025-03-11 | 三诺生物传感股份有限公司 | 一种生理指标检测仪的校准方法和校准装置 |
| CN119395106A (zh) * | 2024-10-24 | 2025-02-07 | 江苏鱼跃凯立特生物科技有限公司 | 一种测试生物样品中分析物浓度的方法和传感器 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5592228A (en) * | 1993-03-04 | 1997-01-07 | Kabushiki Kaisha Toshiba | Video encoder using global motion estimation and polygonal patch motion estimation |
| US6153069A (en) | 1995-02-09 | 2000-11-28 | Tall Oak Ventures | Apparatus for amperometric Diagnostic analysis |
| US5620579A (en) | 1995-05-05 | 1997-04-15 | Bayer Corporation | Apparatus for reduction of bias in amperometric sensors |
| ES2184236T3 (es) | 1997-02-06 | 2003-04-01 | Therasense Inc | Sensor in vitro de analitos de pequeño volumen. |
| US20020159532A1 (en) | 2001-03-23 | 2002-10-31 | Icefyre Semiconductor Corporation | Computational circuits and methods for signal deconstruction/reconstruction in wireless transceivers |
| US8148164B2 (en) * | 2003-06-20 | 2012-04-03 | Roche Diagnostics Operations, Inc. | System and method for determining the concentration of an analyte in a sample fluid |
| ES2820430T3 (es) * | 2005-05-09 | 2021-04-21 | Labrador Diagnostics Llc | Sistemas de fluidos para centros de atención y usos de los mismos |
| CN103558284B (zh) | 2005-07-20 | 2017-04-12 | 安晟信医疗科技控股公司 | 门控电流分析法 |
| AU2006297572B2 (en) | 2005-09-30 | 2012-11-15 | Ascensia Diabetes Care Holdings Ag | Gated Voltammetry |
| US8193804B2 (en) * | 2005-11-16 | 2012-06-05 | Rex Chin-Yih Hong | Device for measuring AC magnetization of materials |
| US8287718B2 (en) | 2006-07-05 | 2012-10-16 | Panasonic Corporation | Liquid sample measurement method and apparatus |
| US20080105024A1 (en) | 2006-11-07 | 2008-05-08 | Bayer Healthcare Llc | Method of making an auto-calibrating test sensor |
| WO2009108239A2 (en) | 2007-12-10 | 2009-09-03 | Bayer Healthcare Llc | Slope-based compensation |
| US20100015006A1 (en) | 2008-07-16 | 2010-01-21 | Tien-Tsai Hsu | Test strip with identification openings and test instrument using the same |
| WO2010077660A1 (en) * | 2008-12-08 | 2010-07-08 | Bayer Healthcare Llc | Biosensor system with signal adjustment |
| US20100167412A1 (en) * | 2008-12-31 | 2010-07-01 | Caibin Xiao | Sensor system for determining concentration of chemical and biological analytes |
| KR101929057B1 (ko) * | 2010-03-22 | 2018-12-13 | 바이엘 헬쓰케어 엘엘씨 | 바이오센서를 위한 잔여 보상 |
| SG186179A1 (en) * | 2010-06-07 | 2013-01-30 | Bayer Healthcare Llc | Slope-based compensation including secondary output signals |
| TWI470226B (zh) * | 2011-03-01 | 2015-01-21 | Eps Bio Technology Corp | 補償血糖濃度的方法 |
| WO2012125727A1 (en) * | 2011-03-14 | 2012-09-20 | Yale University | Calibration of nanostructure sensors |
| EP2747650B1 (en) * | 2011-08-26 | 2023-04-05 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
| EP3315123B1 (en) | 2011-09-21 | 2019-08-21 | Ascensia Diabetes Care Holdings AG | Analysis compensation including segmented signals |
-
2014
- 2014-03-11 CN CN201910675866.5A patent/CN110426436B/zh active Active
- 2014-03-11 US US14/774,684 patent/US10330629B2/en active Active
- 2014-03-11 WO PCT/US2014/023069 patent/WO2014159333A1/en not_active Ceased
- 2014-03-11 CN CN201710107099.9A patent/CN106908501B/zh active Active
- 2014-03-11 CN CN201480025287.1A patent/CN105283765B/zh active Active
- 2014-03-11 EP EP14719898.0A patent/EP2972397B1/en active Active
- 2014-03-11 JP JP2016501142A patent/JP6280203B2/ja active Active
- 2014-03-11 CA CA2902541A patent/CA2902541A1/en not_active Abandoned
- 2014-03-13 TW TW103108990A patent/TWI624666B/zh not_active IP Right Cessation
- 2014-03-13 TW TW107105255A patent/TWI681189B/zh not_active IP Right Cessation
-
2015
- 2015-08-25 IL IL240816A patent/IL240816B/en active IP Right Grant
-
2018
- 2018-01-18 JP JP2018006329A patent/JP6494813B2/ja active Active
-
2019
- 2019-03-05 JP JP2019039413A patent/JP7066649B2/ja active Active
- 2019-04-12 US US16/383,248 patent/US11913898B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6494813B2 (ja) | 分析物濃度決定のシステム誤差補償 | |
| EP2577302B1 (en) | Slope-based compensation method including secondary output signals | |
| JP6539369B2 (ja) | 分析物濃度決定の正規化された較正 | |
| JP2016517517A5 (enExample) | ||
| JP6949811B2 (ja) | 試料分析物濃度の逐次近似 | |
| HK40016909A (en) | System error compensation of analyte concentration determinations | |
| HK1220769B (en) | Progressive approximation of sample analyte concentration | |
| HK1220768B (en) | System error compensation of analyte concentration determinations |